Cargando…
IN.PACT™ Admiral™ drug-coated balloons in peripheral artery disease: current perspectives
Endovascular therapy has evolved as a main treatment option especially in patients with short (<25 cm) femoropopliteal lesion. The latest guideline recommends the use of drug-eluting devices (both drug-coated balloons [DCBs] and drug-eluting stents) in short femoro-popliteal lesions as class IIb...
Autores principales: | Torii, Sho, Kolodgie, Frank D, Virmani, Renu, Finn, Aloke V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385763/ https://www.ncbi.nlm.nih.gov/pubmed/30858737 http://dx.doi.org/10.2147/MDER.S165620 |
Ejemplares similares
-
IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population
por: Chen, Zhong, et al.
Publicado: (2019) -
Long‐term outcomes after paclitaxel‐coated balloon angioplasty of femoropopliteal arteries in Asian patients of the IN.PACT Global Study
por: Ko, Young‐Guk, et al.
Publicado: (2022) -
Long-Term Outcomes of the 150 mm Drug-Coated Balloon Cohort from the IN.PACT Global Study
por: Brodmann, Marianne, et al.
Publicado: (2022) -
Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty
por: Soga, Yoshimitsu, et al.
Publicado: (2020) -
Economics of drug‐coated balloons for arteriovenous fistula stenosis in Japan and Korea based on the IN.PACT AV access trial
por: Chun, Ho Jong, et al.
Publicado: (2022)